Theragnostic Tech Receives NIH Small Business Innovation Research (SBIR) Phase 2 Award

Theragnostic Technologies has received Small Business Innovation Research  (SBIR) Phase 2 grant from the National Institute of Diabestes and Digestive and Kidney Diseases. This SBIR phase 2 project focuses on preclinical investigational new drug (IND) enabling studies of a novel high performance carbon nanostructure-ased magnetic resonance imaging (MRI) contrast agent (CA) to be used to diagnose and monitor patients with renal failure.